U.S. Residential REITs Stock News

Calavo Growers (CVGW) just wrapped up FY 2025 with Q4 revenue of US$124.7 million and basic EPS of US$0.21. Trailing 12 month revenue came in at US$648.4 million and EPS at US$1.11, supported by a trailing net profit margin of 3.1% versus 1.0% in the prior year. Over the last few quarters, revenue has ranged from US$154.4 million to US$190.5 million with quarterly EPS between US$0.21 and US$0.38. This points to a picture of improving profitability that puts margins, rather than top line...

Morgan Stanley (MS) has wrapped up FY 2025 with fourth quarter revenue of US$17.9b and basic EPS of US$2.72, capping a twelve month run that produced total revenue of US$70.3b and basic EPS of US$10.32, alongside a 26.9% rise in earnings and a net profit margin of 23.1% compared with 20.8% the year before. Over the past six quarters, the bank has seen quarterly revenue move from US$15.3b in Q3 2024 to US$17.9b in Q4 2025, while quarterly basic EPS moved from US$1.91 to US$2.72. This set up a...

Wondering if Axsome Therapeutics at around US$174 a share still offers value, or if most of the opportunity has already been priced in? This article is built to help you frame that question clearly. The stock has seen a 3.9% return over the past week and 18.6% over the last 30 days, while year to date it is at a 2.5% decline and up 85.9% over the last year and 155.9% over three years, with a 129.4% return over five years. Recent coverage of Axsome has focused on its position in...

If you are wondering whether Douglas Emmett is priced attractively today, or if the share price still does not reflect its underlying real estate assets, this article explains what the current market value might be telling you. The stock recently closed at US$10.97, with returns of a 1.6% decline over 7 days, a 4.8% decline over 30 days, a 0.9% decline year to date, a 32.8% decline over 1 year and a 51.5% decline over 5 years. This performance may have changed how investors view its risk and...

SELLAS Life Sciences Group (SLS) is back on investor radars after it agreed with the IMPACT AML network to run a European clinical study of its CDK9 inhibitor, SLS009, in high risk newly diagnosed AML. See our latest analysis for SELLAS Life Sciences Group. The new IMPACT AML agreement comes after a volatile spell where traders focused on financing risk, yet the stock still shows a 74.55% 30 day share price return and a very large 1 year total shareholder return. This suggests momentum has...

In recent days, multiple research firms including Benchmark, Wells Fargo, and Truist Financial have issued upbeat coverage on Genius Sports, emphasizing its operating leverage, media monetization approach, and long-term revenue and cash flow ambitions. This wave of positive attention underscores how Genius Sports’ data partnerships and advertising-focused media strategy have become central to its long-term business case. Building on this new analyst optimism around Genius Sports’ media...

Goldman Sachs FY 2025 Earnings Snapshot Goldman Sachs (GS) closed out FY 2025 with fourth quarter revenue of US$15.6 billion and basic EPS of US$14.27 on net income of US$4.4 billion, setting the tone for how investors are reading the latest numbers. Over the past six reported quarters, the bank has seen quarterly revenue move from US$12.3 billion in Q3 2024 to US$13.5 billion in Q4 2024 and then to US$15.6 billion in Q4 2025, while basic EPS shifted from US$8.52 to US$12.14 to US$14.27 over...

If you are wondering whether Oshkosh is actually good value at its current share price, this article walks through the key numbers so you can judge that for yourself. The stock last closed at US$150.77, with returns of 6.4% over 7 days, 16.0% over 30 days, 14.0% year to date, 63.2% over 1 year, 70.4% over 3 years and 71.0% over 5 years, which puts recent valuation questions front and center. Recent headlines around Oshkosh have focused on its position in the capital goods space and investor...

Mereo BioPharma Group recently reported that its Phase 3 Orbit and Cosmic trials of setrusumab in osteogenesis imperfecta missed their primary fracture reduction endpoints but achieved strong statistical improvements in bone mineral density, while also updating investors that its approximately US$41,000,000 cash balance at 31 December 2025 is expected to fund operations to mid-2027. Alongside reassessing the future of setrusumab with partner Ultragenyx, Mereo is pushing ahead with a single...

If you are wondering whether Autoliv’s current share price lines up with its underlying value, this breakdown is designed to walk you through the key numbers that matter. Autoliv shares last closed at US$128.45, with returns of 4.2% over 7 days, 5.9% over 30 days, 5.2% year to date, 36.0% over 1 year and 71.8% over 3 years. This naturally raises questions about how much of this performance is already reflected in the price. Recent attention on Autoliv has centered on its position in vehicle...

If you are wondering whether Fiserv's current share price reflects its true worth, you are not alone. This article focuses squarely on what the numbers say about value. Fiserv shares last closed at US$67.50, with returns of a 1.8% decline over 7 days, a 2.1% decline over 30 days, a 2.9% gain year to date, and declines of 67.0% over 1 year, 34.6% over 3 years and 38.2% over 5 years. Recent headlines around Fiserv have focused on its role as a major provider of payments and financial...

General American Investors Company recently renewed its preferred stock repurchase program, authorizing buybacks of up to 1,601,553 preferred shares when they trade below the US$25 liquidation preference, and Vice President Eugene Stark purchased 4,000 preferred shares for US$99,920. Together, the renewed buyback capacity and insider purchase highlight how the firm is actively managing its capital structure while signaling internal commitment to the preferred stock. Next, we will examine how...

On January 8, 2026, BioLife Solutions, Inc. reported preliminary fourth-quarter and full-year 2025 unaudited revenue from continuing operations, indicating a 20% increase in fourth-quarter revenue that surpassed the high end of its previously raised 2025 revenue guidance, and also disclosed that Chief Quality and Operations Officer Karen Foster had earlier notified the company of her decision to retire effective March 31, 2026. This combination of stronger-than-expected revenue performance...

In the past week, digital auto insurer Root faced renewed scrutiny after a Wells Fargo analyst highlighted weakening operating cash flow, reduced available capital, and an underwriting loss reflected in a 102% combined ratio. At the same time, Root Insurance and personal finance platform Kikoff announced an embedded insurance partnership, integrating Root’s data-driven auto policy quoting and purchasing directly into the Kikoff app to broaden access to mobile-first coverage. We’ll now...

Apogee Enterprises, Inc.'s ( NASDAQ:APOG ) earnings announcement last week didn't impress shareholders. However, our...

Shareholders in Applied Digital Corporation ( NASDAQ:APLD ) may be thrilled to learn that the analysts have just...

PureCycle Technologies recently announced a collaboration with Churchill Container and 4ocean to supply Run It Back souvenir cups made with its PureFive recycled resin at the College Football Playoff National Championship, while also revising its construction agreement for a future recycling facility in Augusta, Georgia, including a US$500,000 payment to AEDA and updated project milestones. Together, the high-visibility sustainability initiative at a major sporting event and the recalibrated...

Kopin Corporation recently announced that Theon International placed a US$1.0 million development order for its 960p DarkWAVE™ module, moving the AR‑ and thermal‑enabled clip‑on night-vision platform from prototype to production readiness for international defense customers in 2026. This first meaningful DarkWAVE order targets the large aftermarket of an estimated more than 2 million fielded night-vision goggles worldwide, potentially turning existing systems into AR-enabled devices without...

Recently, TD Cowen and UBS both upgraded Enhabit to Buy, signaling a shift in analyst opinion on the home health and hospice provider. This cluster of upgrades suggests large institutions are reassessing Enhabit’s risk‑reward profile in light of its evolving operating backdrop. Next, we’ll examine how this renewed analyst confidence might influence Enhabit’s investment narrative, particularly around reimbursement resilience and growth. AI is about to change healthcare. These 30 stocks are...

As the United States stock market experiences a resurgence, with major indices like the Nasdaq, Dow Jones Industrial Average, and S&P 500 climbing on strong tech earnings and easing geopolitical tensions, investors are increasingly focused on identifying opportunities that may be undervalued. In this environment of fluctuating oil prices and robust tech performance, discerning stocks that are priced below their estimated value can offer potential advantages for those looking to capitalize on...

As the U.S. stock market experiences a surge, driven by strong performances in the tech sector and easing geopolitical tensions, investors are keenly observing growth companies that insiders are backing with significant ownership stakes. In this environment of rising indices and fluctuating oil prices, stocks with high insider ownership can offer an added layer of confidence for investors seeking to align with those who have intimate knowledge of their company's potential.

As the U.S. stock market experiences a surge, led by tech rallies and tempered oil prices, investors are keenly observing opportunities across various sectors. Penny stocks, while often considered niche due to their lower price points and smaller market capitalizations, continue to attract attention for their potential growth prospects. These stocks can offer a compelling mix of affordability and growth potential when backed by strong financials; let's explore several that might stand out in...

Compass Therapeutics has appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer, with both roles effective January 1, 2026, adding experienced oncology leadership across commercial and clinical development functions. These hires bring deep experience in successful oncology drug launches and advancing immuno-oncology programs through pivotal trials and regulatory approvals, potentially strengthening Compass Therapeutics’ execution capabilities. Next,...

EPR Properties’ Board of Trustees has declared a past monthly cash dividend of US$0.295 per common share, payable on February 17, 2026 to shareholders of record as of January 30, 2026, equivalent to an annualized US$3.54 per share. This reaffirmed payout, alongside recent balance sheet moves and operational updates, underlines the REIT’s continued emphasis on consistent income for shareholders. We’ll now examine how the reaffirmed monthly dividend interacts with EPR’s experiential-focused...